| 摘要 |
<p>Formulations of an interleukin-1 (IL-1) antagonist are provided including pre-lyophilized formulation, a reconstiotuted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-I antagonist is an IL-I trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4,6,8, 10, 12,14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence of SEQ ID NO: 10.</p> |
